**Návrh**

**VYHLÁŠKA**

**Ministerstva zdravotníctva Slovenskej republiky**

**z ...... 2021,**

**ktorou sa ustanovujú podmienky výpočtu prahovej hodnoty pre účely posúdenia nákladovej efektívnosti lieku**

Ministerstvo zdravotníctva Slovenskej republiky podľa [§ 7 ods. 3 zákona č. 363/2011 Z. z.](aspi://module='ASPI'&#38;link='578/2004%20Z.z.%252379'&) o rozsahu a podmienkach úhrady liekov, zdravotníckych pomôcok a dietetických potravín na základe verejného zdravotného poistenia a o zmene a doplnení niektorých zákonov v znení neskorších predpisov (ďalej len „zákon“) ustanovuje:

§ 1

Prahová hodnota posudzovaného lieku podľa § 7 ods. 3 zákona nesmie prekročiť:

1. za rozdiel väčší ako 0 a menší ako 0,33 získaného života štandardizovanej kvality v porovnaní s inou medicínskou intervenciou hodnotu dvojnásobku hodnoty hrubého domáceho produktu (ďalej len „HDP“) na obyvateľa,
2. za rozdiel 0,33 a viac získaného života štandardizovanej kvality v porovnaní s inou medicínskou intervenciou hodnotu trojnásobku hodnoty HDP na obyvateľa.

§ 2

Prahová hodnota posudzovaného lieku, ktorý je liekom na ojedinelé ochorenia1) alebo liekom na inovatívnu liečbu2), podľa § 7 ods. 3 zákona nesmie prekročiť:

1. za rozdiel väčší ako [\_\_\_] a menší ako [\_\_\_] získaného života štandardizovanej kvality hodnotu trojnásobku HDP na obyvateľa,
2. za rozdiel väčší ako [\_\_\_] a menší ako [\_\_\_] získaného života štandardizovanej kvality hodnotu desaťnásobku HDP na obyvateľa,
3. v intervale medzi viac ako 6 získaných mesiacov a menej ako 20 získaných rokov života štandardizovanej kvality hodnotu, ktorá prislúcha pomeru medzi hodnotami podľa písmena a) a b) k počtu príslušných získaných mesiacov alebo rokov života štandardizovanej kvality.

§ 3

Táto vyhláška nadobúda účinnosť dňom nadobudnutia účinnosti novely zákona. Oznámenie o nadobudnutí účinnosti novely zákona zverejní Minister zdravotníctva Slovenskej republiky v Zbierke zákonov Slovenskej republiky.

1. Článok 2 písm. b) Nariadenia Európskeho parlamentu a rady (ES) č. 141/2000 zo 16. decembra 1999 o liekoch na ojedinelé ochorenia.
2. Článok 2 Nariadenia Európskeho parlamentu a Rady (ES) č. 1394/2007 z 13. novembra 2007 o liekoch na inovatívnu liečbu, ktorým sa mení a dopĺňa smernica 2001/83/ES a nariadenie (ES) č. 726/2004.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  |  |  | | --- | --- | --- | | Príloha | | | | Zoznam liečiv, ktoré sa musia predpisovať len uvedením názvu liečiva | | | | ATC | Liečivo | p.o. | | A01AA01 | Fluorid sodný | p.o. | | A02BC01 | Omeprazol | p.o. | | A02BC02 | Pantoprazol | p.o. | | A02BC03 | Lanzoprazol | p.o. | | A02BC05 | Ezomeprazol | p.o. | | A02BX02 | Sukralfát | p.o. | | A03AA04 | Mebeverín | p.o. | | A03AD02 | Drotaverín | p.o. | | A03AX04 | Pinavérium | p.o. | | A03BB01 | Butylskopolamín | p.o. | | A03FA01 | Metoklopramid | p.o. | | A03FA03 | Domperidón | p.o. | | A03FA07 | Itoprid hydrochlorid | p.o. | | A04AA01 | Ondasetrón | p.o. | | A04AA02 | Granisetrón | p.o. | | A04AA05 | Palonosetrón | p.o. | | A04AD12 | Aprepitant | p.o. | | A05AA02 | Kyselina ursodeoxycholínová | p.o. | | A05BA03 | Silymarín | p.o. | | A06AD11 | Laktulóza | p.o. | | A06AH03 | Naloxegol | p.o. | | A06AX05 | Prukaloprid | p.o. | | A07AA11 | Rifaximín | p.o. | | A07EA06 | Budezonid | p.o. | | A07EC01 | Sulfasalazín | p.o. | | A07EC02 | Mesalazín | p.o. | | A07FA | Antidiarhoické mikroorganizmy | p.o. | | A07XA05 | Telotristát | p.o. | | A10BA02 | Metformín | p.o. | | A10BB01 | Glibenklamid | p.o. | | A10BB07 | Glipizid | p.o. | | A10BB08 | Gliquidon | p.o. | | A10BB09 | Gliklazid | p.o. | | A10BB12 | Glimepirid | p.o. | | A10BF01 | Akarbóza | p.o. | | A10BG02 | Roziglitazón | p.o. | | A10BG03 | Pioglitazón | p.o. | | A10BH01 | Sitagliptín | p.o. | | A10BH02 | Vildagliptín | p.o. | | A10BH03 | Saxagliptín | p.o. | | A10BH04 | Alogliptín | p.o. | | A10BH05 | Linagliptín | p.o. | | A10BK03 | Empagliflozín | p.o. | | A10BX02 | Repaglinid | p.o. | | A10BX09 | Dapagliflozín | p.o. | | A10BX11 | Kanagliflozín | p.o. | | A11CA01 | Retinol | p.o. | | A11CC01 | Ergokalciferol | p.o. | | A11CC03 | Alfakalcidol | p.o. | | A11CC04 | Kalcitriol | p.o. | | A11CC05 | Cholekalciferol | p.o. | | A12AA | Vápnik | p.o. | | A12AA04 | Uhličitan vápenatý | p.o. | | A12BA | Draslík, horčík | p.o. | | A12BA01 | Chlorid draselný | p.o. | | A12CC06 | Mliečnan horečnatý | p.o. | | A12CC30 | Horčík | p.o. | | A16AX01 | Kyselina tioktová | p.o. | | A16AX04 | Nitizinón | p.o. | | A16AX06 | Miglustat | p.o. | | A16AX07 | Sapropterin | p.o. | | A16AX09 | Glycerolfenylbutyrát | p.o. | | A16AX10 | Eliglustat | p.o. | | B01AB11 | Sulodexid | p.o. | | B01AC04 | Klopidogrel | p.o. | | B01AC05 | Ticlopidín | p.o. | | B01AC06 | Kyselina acetylsalicylová | p.o. | | B01AC10 | Indobufén | p.o. | | B01AC22 | Prasugrel | p.o. | | B01AC23 | Cilostazol | p.o. | | B01AC24 | Tikagrelor | p.o. | | B01AC27 | Selexipag | p.o. | | B01AE07 | Dabigatranetexilát | p.o. | | B01AF02 | Apixabán | p.o. | | B01AF03 | Edoxabán | p.o. | | B01AX06 | Rivaroxaban | p.o. | | B02AA03 | Kyselina aminometylbenzoová | p.o. | | B02BA01 | Fytomenadión | p.o. | | B02BX01 | Etamsylát | p.o. | | B02BX05 | Eltrombopag | p.o. | | B03AA07 | Síran železnatý | p.o. | | B03BB01 | Kyselina listová | p.o. | | C01BA08 | Prajmalín | p.o. | | C01BC03 | Propafenón | p.o. | | C01BD01 | Amiodarón | p.o. | | C01BD07 | Dronedarón | p.o. | | C01DA08 | Izosorbid dinitrát | p.o. | | C01DA14 | Izosorbid mononitrát | p.o. | | C01DX12 | Molsidomín | p.o. | | C01EB15 | Trimetazidín | p.o. | | C01EB17 | Ivabradín | p.o. | | C02AB01 | L- metyldopa | p.o. | | C02AC05 | Moxonidín | p.o. | | C02AC06 | Rilmenidín | p.o. | | C02CA04 | Doxazosín | p.o. | | C02CA06 | Urapidil | p.o. | | C02KX01 | Bosentan | p.o. | | C02KX02 | Ambrisentan | p.o. | | C02KX04 | Macitentan | p.o. | | C02KX05 | Riociguát | p.o. | | C03AA03 | Hydrochlóroti azid | p.o. | | C03BA | Sulfonamidy, samotné (metipamid) | p.o. | | C03BA11 | Indapamid | p.o. | | C03CA01 | Furosemid | p.o. | | C03DA01 | Spironolaktón | p.o. | | C03DA04 | Eplerenón | p.o. | | C04AD03 | Pentoxifylín | p.o. | | C04AX21 | Naftidrofuryl | p.o. | | C05BX01 | Dobesilát vápenatý | p.o. | | C05CA54 | Troxerutín | p.o. | | C05CX01 | Tribenozid | p.o. | | C07AA | Betablokátory, jednozložkové, neselektívne (metipranolol) | p.o. | | C07AA05 | Propranolol | p.o. | | C07AA07 | Sotalol | p.o. | | C07AA17 | Bopindolol | p.o. | | C07AB02 | Metoprolol | p.o. | | C07AB03 | Atenolol | p.o. | | C07AB05 | Betaxolol | p.o. | | C07AB07 | Bisoprolol | p.o. | | C07AB08 | Celiprolol | p.o. | | C07AB12 | Nebivolol | p.o. | | C07AG02 | Carvedilol | p.o. | | C08CA01 | Amlodipín | p.o. | | C08CA02 | Felodipín | p.o. | | C08CA03 | Isradipín | p.o. | | C08CA05 | Nifedipín | p.o. | | C08CA06 | Nimodipín | p.o. | | C08CA08 | Nitrendipín | p.o. | | C08CA09 | Lacidipín | p.o. | | C08CA13 | Lerkanidipín | p.o. | | C08DA01 | Verapamil | p.o. | | C08DB01 | Diltiazem | p.o. | | C09AA01 | Kaptopril | p.o. | | C09AA02 | Enalapril | p.o. | | C09AA03 | Lizinopril | p.o. | | C09AA04 | Perindopril (arginín) | p.o. | | C09AA04 | Perindopril (terc-butylamín) | p.o. | | C09AA05 | Ramipril | p.o. | | C09AA06 | Quinapril | p.o. | | C09AA09 | Fosinopril | p.o. | | C09AA10 | Trandolapril | p.o. | | C09AA11 | Spirapril | p.o. | | C09AA13 | Moexipril | p.o. | | C09AA15 | Zofenopril | p.o. | | C09AA16 | Imidapril | p.o. | | C09CA01 | Losartan | p.o. | | C09CA02 | Eprosartan | p.o. | | C09CA03 | Valsartan | p.o. | | C09CA04 | Irbesartan | p.o. | | C09CA06 | Candesartan | p.o. | | C09CA07 | Telmisartan | p.o. | | C09XA02 | Aliskiren | p.o. | | C10AA01 | Simvastatín | p.o. | | C10AA02 | Lovastatín | p.o. | | C10AA04 | Fluvastatín | p.o. | | C10AA05 | Atorvastatín | p.o. | | C10AA07 | Rosuvastatín | p.o. | | C10AB05 | Fenofibrát | p.o. | | C10AB08 | Ciprofibrát | p.o. | | C10AC01 | Cholestyramín | p.o. | | C10AX06 | Estery omega-3-kyselín | p.o. | | C10AX09 | Ezetimib | p.o. | | D01BA02 | Terbinafín | p.o. | | D05BB02 | Acitretín | p.o. | | D10BA01 | Izotretinoín | p.o. | | G01AX05 | Nifuratel | p.o. | | G02CB01 | Bromkriptín | p.o. | | G02CB03 | Kabergolín | p.o. | | G02CB04 | Quinagolid | p.o. | | G03BA03 | Testosterón | p.o. | | G03BB01 | Mesterolón | p.o. | | G03CA03 | Estradiol | p.o. | | G03CA04 | Estriol | p.o. | | G03CX01 | Tibolón | p.o. | | G03D | Dienogest | p.o. | | G03DA02 | Medroxyprogesterón | p.o. | | G03DA04 | Progesterón | p.o. | | G03DB01 | Dydrogesterón | p.o. | | G03DB04 | Nomegestrol acetát | p.o. | | G03DC02 | Noretisterón | p.o. | | G03GB02 | Klomifén | p.o. | | G03HA01 | Cyproterón | p.o. | | G03XA01 | Danazol | p.o. | | G03XB02 | Ulipristal | p.o. | | G03XC01 | Raloxifén hydrochlorid | p.o. | | G04BC | Rozpúšťadlá močových kameňov | p.o. | | G04BD04 | Oxybutynín | p.o. | | G04BD06 | Propiverín | p.o. | | G04BD07 | Tolterodín | p.o. | | G04BD08 | Solifenacín | p.o. | | G04BD09 | Trospium chlorid | p.o. | | G04BD10 | Darifenacín | p.o. | | G04BD11 | Fesoterodín | p.o. | | G04BD12 | Mirabegron | p.o. | | G04BE03 | Sildenafil | p.o. | | G04CA01 | Alfuzosín | p.o. | | G04CA02 | Tamsulosín | p.o. | | G04CA03 | Terazosín | p.o. | | G04CA04 | Silodozín | p.o. | | G04CB01 | Finasterid | p.o. | | G04CB02 | Dutasterid | p.o. | | H01BA02 | Dezmopresín | p.o. | | H02AA02 | Fludrokortizón | p.o. | | H02AB02 | Dexametazón | p.o. | | H02AB04 | Metylprednizolón | p.o. | | H02AB07 | Prednizón | p.o. | | H02AB08 | Triamcinolón | p.o. | | H03AA01 | Levotyroxín - sodná soľ | p.o. | | H03BA02 | Propyltiouracil | p.o. | | H03BB01 | Karbimazol | p.o. | | H03BB02 | Tiamazol | p.o. | | H05BX01 | Cinakalcet | p.o. | | H05BX02 | Parikalcitol | p.o. | | J01AA02 | Doxycyklín | p.o. | | J01CA04 | Amoxicilín | p.o. | | J01CE02 | Fenoxymetylpenicilín | p.o. | | J01CE06 | Penamecilín | p.o. | | J01CR04 | Sultamicilín | p.o. | | J01DB01 | Cefalexín | p.o. | | J01DB05 | Cefadroxil | p.o. | | J01DC02 | Cefuroxim | p.o. | | J01DC04 | Cefaklor | p.o. | | J01DC10 | Cefprozil | p.o. | | J01DD08 | Cefixime | p.o. | | J01DD14 | Ceftibutén | p.o. | | J01EA01 | Trimetoprim | p.o. | | J01FA02 | Spiramycín | p.o. | | J01FA06 | Roxitromycín | p.o. | | J01FA09 | Klaritromycín | p.o. | | J01FA10 | Azitromycín | p.o. | | J01FF01 | Klindamycín | p.o. | | J01MA01 | Ofloxacín | p.o. | | J01MA02 | Ciprofloxacín | p.o. | | J01MA03 | Pefloxacín | p.o. | | J01MA06 | Norfloxacín | p.o. | | J01MA12 | Levofloxacín | p.o. | | J01MA14 | Moxifloxacín | p.o. | | J01MA17 | Prulifloxacín | p.o. | | J01XX01 | Fosfomycín | p.o. | | J01XX08 | Linezolid | p.o. | | J02AB02 | Ketokonazol | p.o. | | J02AC01 | Flukonazol | p.o. | | J02AC02 | Itrakonazol | p.o. | | J02AC03 | Vorikonazol | p.o. | | J02AC04 | Posakonazol | p.o. | | J04AB02 | Rifampicín | p.o. | | J04AC01 | Izoniazid | p.o. | | J04AK02 | Etambutol | p.o. | | J04BA02 | Dapson | p.o. | | J05AB | Brivudin | p.o. | | J05AB01 | Acyklovir | p.o. | | J05AB09 | Famciklovír | p.o. | | J05AB11 | Valacyklovir | p.o. | | J05AB14 | Valgancyklovir | p.o. | | J05AE 08 | Atazanavir | p.o. | | J05AE01 | Sachinavir | p.o. | | J05AE02 | Indinavír | p.o. | | J05AE03 | Ritonavir | p.o. | | J05AE06 | Lopinavir | p.o. | | J05AE07 | Fosamprenavir | p.o. | | J05AE09 | Tipranavir | p.o. | | J05AE10 | Darunavir | p.o. | | J05AF02 | Didanozín | p.o. | | J05AF04 | Stavudin | p.o. | | J05AF05 | Lamivudin | p.o. | | J05AF06 | Abakavir | p.o. | | J05AF07 | Tenofovir | p.o. | | J05AF08 | Adefovir | p.o. | | J05AF10 | Entekavir | p.o. | | J05AF11 | Telbivudín | p.o. | | J05AG01 | Nevirapin | p.o. | | J05AG03 | Efavirenz | p.o. | | J05AG04 | Etravirin | p.o. | | J05AG05 | Rilpivirín | p.o. | | J05AX05 | Inozín pranobex | p.o. | | J05AX08 | Raltegravír | p.o. | | J05AX12 | Dolutegravir | p.o. | | J05AX15 | Sofosbuvir | p.o. | | L01AA01 | Cyklofosfamid | p.o. | | L01AA02 | Chlorambucil | p.o. | | L01AA03 | Melfalan | p.o. | | L01AD02 | Lomustín | p.o. | | L01AX03 | Temozolomid | p.o. | | L01BB02 | Merkaptopurín | p.o. | | L01BB05 | Fludarabín | p.o. | | L01BC06 | Kapecitabin | p.o. | | L01CA04 | Vinorelbin | p.o. | | L01DB06 | Idarubicín | p.o. | | L01XE01 | Imatinib | p.o. | | L01XE02 | Gefitinib | p.o. | | L01XE03 | Erlotinib | p.o. | | L01XE04 | Sunitinib | p.o. | | L01XE05 | Sorafenib | p.o. | | L01XE06 | Dasatinib | p.o. | | L01XE07 | Lapatinib | p.o. | | L01XE08 | Nilotinib | p.o. | | L01XE10 | Everolimus | p.o. | | L01XE11 | Pazopanib | p.o. | | L01XE12 | Vandetanib | p.o. | | L01XE13 | Afatinib | p.o. | | L01XE24 | Ponatinib | p.o. | | L01XE26 | Cabozantinib | p.o. | | L01XE27 | Ibrutinib | p.o. | | L01XE39 | Midostaurín | p.o. | | L01XX05 | Hydroxyurea | p.o. | | L01XX11 | Estramustin | p.o. | | L01XX14 | Tretinoín | p.o. | | L01XX17 | Topotekan | p.o. | | L01XX23 | Mitotan | p.o. | | L01XX25 | Bexaroten | p.o. | | L01XX35 | Anagrelid | p.o. | | L01XX43 | Vismodegib | p.o. | | L01XX46 | Olaparib | p.o. | | L01XX52 | Venetoklax | p.o. | | L02AB01 | Megestrol | p.o. | | L02BA01 | Tamoxifén | p.o. | | L02BA02 | Toremifén | p.o. | | L02BB01 | Flutamid | p.o. | | L02BB03 | Bikalutamid | p.o. | | L02BB04 | Enzalutamid | p.o. | | L02BG03 | Anastrozol | p.o. | | L02BG04 | Letrozol | p.o. | | L02BG06 | Exemestan | p.o. | | L02BX03 | Abiraterón | p.o. | | L04AA13 | Leflunomid | p.o. | | L04AA27 | Fingolimod | p.o. | | L04AA29 | Tofacitinib | p.o. | | L04AA31 | Teriflunomid | p.o. | | L04AA32 | Apremilast | p.o. | | L04AA37 | Baricitinib | p.o. | | L04AA40 | Kladribín | p.o. | | L04AX03 | Metotrexát | p.o. | | L04AX04 | Lenalidomid | p.o. | | M01AB05 | Diklofenak | p.o. | | M01AB16 | Aceklofenak | p.o. | | M01AC01 | Piroxikam | p.o. | | M01AC05 | Lornoxikam | p.o. | | M01AC06 | Meloxikam | p.o. | | M01AE01 | Ibuprofén | p.o. | | M01AE02 | Naproxén | p.o. | | M01AE03 | Ketoprofén | p.o. | | M01AE09 | Flurbiprofén | p.o. | | M01AE11 | Kyselina tiaprofénová | p.o. | | M01AE17 | Dexketoprofen | p.o. | | M01AH01 | Celekoxib | p.o. | | M01AH05 | Etorikoxib | p.o. | | M01AX05 | Glukozamín | p.o. | | M01AX17 | Nimesulid | p.o. | | M01AX21 | Diacereín | p.o. | | M01AX25 | Chondroitínsulfát | p.o. | | M01CC01 | Penicilamín | p.o. | | M03BX01 | Baklofén | p.o. | | M03BX02 | Tizanidín | p.o. | | M03BX04 | Tolperizón | p.o. | | M03BX07 | Tetrazepam | p.o. | | M04AA01 | Allopurinol | p.o. | | M04AA03 | Febuxostat | p.o. | | M04AC01 | Kolchicín | p.o. | | M05BA02 | Kyselina klodrónová | p.o. | | M05BA04 | Kyselina alendrónová | p.o. | | M05BA06 | Kyselina ibandrónová | p.o. | | M05BA07 | Kyselina risedrónová | p.o. | | M05BX03 | Stroncium ranelát | p.o. | | M09AX03 | Ataluren | p.o. | | N02AA08 | Dihydrokodeín | p.o. | | N02AX02 | Tramadol | p.o. | | N02BA01 | Kyselina acetylsalicylová | p.o. | | N02BB02 | Metamizol, sodná soľ | p.o. | | N02BE01 | Paracetamol | p.o. | | N02BG07 | Maleinát flupirtínu | p.o. | | N02CC01 | Sumatriptan | p.o. | | N02CC03 | Zolmitriptan | p.o. | | N02CC04 | Rizatriptan | p.o. | | N02CC06 | Eletriptan | p.o. | | N02CC07 | Frovatriptan | p.o. | | N02CX01 | Pizotifén | p.o. | | N03AA02 | Fenobarbital | p.o. | | N03AD01 | Etosuximid | p.o. | | N03AF01 | Karbamazepín | p.o. | | N03AF02 | Oxkarbazepín | p.o. | | N03AF03 | Rufinamid | p.o. | | N03AF04 | Eslikarbazepín acetát | p.o. | | N03AG01 | Kyselina valproová | p.o. | | N03AG04 | Vigabatrín | p.o. | | N03AX03 | Sultiam | p.o. | | N03AX09 | Lamotrigín | p.o. | | N03AX11 | Topiramát | p.o. | | N03AX12 | Gabapentín | p.o. | | N03AX14 | Levetiracetam | p.o. | | N03AX15 | Zonisamid | p.o. | | N03AX16 | Pregabalín | p.o. | | N03AX18 | Lakosamid | p.o. | | N03AX22 | Perampanel | p.o. | | N03AX23 | Brivaracetam | p.o. | | N04AA02 | Biperidén | p.o. | | N04BB01 | Amantadín | p.o. | | N04BC04 | Ropinirol | p.o. | | N04BC05 | Pramipexol | p.o. | | N04BD02 | Rasagilín | p.o. | | N04BX01 | Tolkapon | p.o. | | N04BX02 | Entakapon | p.o. | | N05AA01 | Chlórpromazín | p.o. | | N05AA02 | Levomepromazín | p.o. | | N05AD01 | Haloperidol | p.o. | | N05AE03 | Sertindol | p.o. | | N05AE04 | Ziprasidón | p.o. | | N05AF03 | Chlórprotixén | p.o. | | N05AF05 | Zuklopentixol | p.o. | | N05AH02 | Klozapín | p.o. | | N05AH03 | Olanzapín | p.o. | | N05AH04 | Kvetiapín | p.o. | | N05AL01 | Sulpirid | p.o. | | N05AL03 | Tiaprid | p.o. | | N05AL05 | Amisulprid | p.o. | | N05AN01 | Lítium | p.o. | | N05AX08 | Risperidón | p.o. | | N05AX11 | Zotepín | p.o. | | N05AX12 | Aripiprazol | p.o. | | N05AX13 | Paliperidón | p.o. | | N05AX15 | Kariprazín | p.o. | | N05BA01 | Diazepam | p.o. | | N05BA04 | Oxazepam | p.o. | | N05BA08 | Bromazepam | p.o. | | N05BA09 | Klobazam | p.o. | | N05BA12 | Alprazolam | p.o. | | N05BB01 | Hydroxyzín | p.o. | | N05BE01 | Buspiron | p.o. | | N05BX01 | Mefenoxalón | p.o. | | N05CD08 | Midazolam | p.o. | | N05CD13 | Cinolazepam | p.o. | | N05CF01 | Zopiklón | p.o. | | N05CF02 | Zolpidem | p.o. | | N05CH01 | Melatonín | p.o. | | N06AA02 | Imipramín | p.o. | | N06AA04 | Klomipramín | p.o. | | N06AA08 | Dibenzepín | p.o. | | N06AA09 | Amitriptylín | p.o. | | N06AA16 | Dosulepín | p.o. | | N06AA21 | Maprotilín | p.o. | | N06AB03 | Fluoxetín | p.o. | | N06AB04 | Citalopram | p.o. | | N06AB05 | Paroxetin | p.o. | | N06AB06 | Sertralin | p.o. | | N06AB08 | Fluvoxamin | p.o. | | N06AB10 | Escitalopram | p.o. | | N06AG02 | Moklobemid | p.o. | | N06AX03 | Mianserin | p.o. | | N06AX05 | Trazodon | p.o. | | N06AX11 | Mirtazapín | p.o. | | N06AX12 | Bupropión | p.o. | | N06AX14 | Tianeptín | p.o. | | N06AX16 | Venlafaxín | p.o. | | N06AX17 | Milnacipran | p.o. | | N06AX21 | Duloxetín | p.o. | | N06AX22 | Agomelatín | p.o. | | N06AX26 | Vortioxetín | p.o. | | N06BA07 | Modafinil | p.o. | | N06BA09 | Atomoxetín | p.o. | | N06BX03 | Piracetam | p.o. | | N06BX18 | Vinpocetín | p.o. | | N06DA02 | Donepezil | p.o. | | N06DA03 | Rivastigmín | p.o. | | N06DA04 | Galantamín | p.o. | | N06DX01 | Memantín | p.o. | | N06DX02 | Ginkgo biloba | p.o. | | N07AA01 | Neostigmín | p.o. | | N07AA02 | Pyridostigmín | p.o. | | N07AA03 | Distigmín | p.o. | | N07BB03 | Akamprosat | p.o. | | N07BB04 | Naltrexón | p.o. | | N07BB05 | Nalmefén | p.o. | | N07CA01 | Betahistín | p.o. | | N07CA02 | Cinarizín | p.o. | | N07XX04 | Nátriumoxybát | p.o. | | N07XX05 | Amifampridín | p.o. | | N07XX06 | Tetrabenazín | p.o. | | N07XX09 | Dimetylfumarát | p.o. | | P01AB01 | Metronidazol | p.o. | | P01AB03 | Ornidazol | p.o. | | P01BA01 | Chlorochin | p.o. | | P01BA02 | Hydroxychlorochin | p.o. | | P01BC02 | Meflochin | p.o. | | P02CA01 | Mebendazol | p.o. | | P02CA03 | Albendazol | p.o. | | R03BC01 | Nátrium chromoglykolát | p.o. | | R03CC02 | Salbutamol | p.o. | | R03CC08 | Prokaterol | p.o. | | R03CC13 | Klenbuterol | p.o. | | R03DA04 | Teofylín | p.o. | | R03DC01 | Zafirlukast | p.o. | | R03DC03 | Montelukast | p.o. | | R03DX07 | Roflumilast | p.o. | | R05DA04 | Kodeín | p.o. | | R05CB01 | Acetylcysteín | p.o. | | R05CB15 | Erdosteín | p.o. | | R06AA02 | Difenhydramín | p.o. | | R06AA04 | Klemastin | p.o. | | R06AB03 | Dimetindén | p.o. | | R06AD02 | Prometazín | p.o. | | R06AD03 | Tietilperazín | p.o. | | R06AE07 | Cetirizín | p.o. | | R06AE09 | Levocetirizín | p.o. | | R06AX | Ostatné antihistaminiká na systémové použitie | p.o. | | R06AX02 | Cyproheptadin | p.o. | | R06AX13 | Loratadin | p.o. | | R06AX17 | Ketotifén | p.o. | | R06AX26 | Fexofenadín | p.o. | | R06AX27 | Desloratadín | p.o. | | R06AX28 | Rupatadín | p.o. | | R06AX29 | Bilastín | p.o. | | S01EC01 | Acetazolamid | p.o. | | V03AC03 | Deferasirox | p.o. | | V03AE01 | Sulfonát polystyrénu | p.o. | | V03AE02 | Sevelamer karbonát | p.o. | | V03AE03 | Hydrát uhličitanu lantanitého | p.o. | | V03AF03 | Kalcium folinát | p.o. | |